CAS 361440-67-7 Purity >98.5% (HPLC) Factory

Short Description:

(1S,3S,5S)-3-(Aminocarbonyl)-2-Azabicyclo [3.1.0]hexane-2-Carboxylic Acid tert-Butyl Ester

CAS: 361440-67-7

Purity: >98.5% (HPLC)

Appearance: White Powder

Intermediate of API (CAS: 361442-04-8)

E-Mail: alvin@ruifuchem.com

Send email to us

Product Detail

Product Tags

Description:

Ruifu Chemical Supply Related Intermediates
CAS 361442-04-8
CAS 945667-22-1
(R)-1-Boc-3-Aminopiperidine CAS 188111-79-7
(R)-(-)-3-Aminopiperidine Dihydrochloride CAS 334618-23-4
Boc-3-Hydroxy-1-Adamantyl-D-Glycine CAS 361442-00-4
(1S,3S,5S)-3-(Aminocarbonyl)-2-Azabicyclo [3.1.0]hexane-2-Carboxylic Acid tert-Butyl Ester CAS 361440-67-7
2-(3-Hydroxy-1-Adamantyl)-2-Oxoacetic Acid CAS 709031-28-7

Chemical Properties:

Chemical Name	(1S,3S,5S)-3-(Aminocarbonyl)-2-Azabicyclo[3.1.0]hexane-2-Carboxylic Acid tert-Butyl Ester
Synonyms	N-Boc-L-cis-4,5-Methanoprolineamide; N-Boc-cis-4,5-Methano-L-Prolinamide; tert-Butyl (1S,3S,5S)-3-Carbamoyl-2-Azabicyclo[3.1.0]hexane-2-Carboxylate
CAS Number	361440-67-7
CAT Number	RF-PI1990
Stock Status	In Stock, Production Scale Up to Tons
Molecular Formula	C11H18N2O3
Molecular Weight	226.27
Boiling Point	388.9±21.0℃
Density	1.228
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Appearance	White Powder
Purity / Analysis Method	>98.5% (HPLC)
Loss on Drying	<0.50%
Residue on Ignition	<0.20%
Individual Impurities	<1.00%
Total Impurities	<1.50%
Test Standard	Enterprise Standard
Usage	Intermediate of API (CAS: 361442-04-8)

Package & Storage:

Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement

Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture

Advantages:

FAQ:

Application:

(1S,3S,5S)-3-(Aminocarbonyl)-2-Azabicyclo[3.1.0]hexane-2-Carboxylic Acid tert-Butyl Ester (CAS: 361440-67-7) is an intermediate of API (CAS: 361442-04-8). (CAS: 361442-04-8) is an oral hypoglycemic (anti-diabetic drug) of the dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. Early development was solely by Bristol-Myers Squibb; in 2007 AstraZeneca joined with Bristol-Myers Squibb to co-develop the final compound and collaborate on the marketing of the drug. In June 2008, it was announced that Onglyza would be the trade name under which will be marketed. API (CAS: 361442-04-8) is used as monotherapy or in combination with other drugs for the treatment of type 2 diabetes. It is absorbed rapidly after oral administration and has a pharmacokinetic profile compatible with once daily dosing. It plays the role through inhibiting GLP-l degradation. GLP-I is the hormones naturally produced in the intestine after taking food.